Impact of the swallowable Allurion intragastric balloon on body weight and composition: An Ecuadorian experience.

IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM
Clinical Obesity Pub Date : 2024-09-22 DOI:10.1111/cob.12705
Bernarda Patiño Araujo, Karla Elizabeth Duque Jácome, María Emilia Salgado Báez, Gabriel Villavicencio Logroño, Napoleón Salgado Macías
{"title":"Impact of the swallowable Allurion intragastric balloon on body weight and composition: An Ecuadorian experience.","authors":"Bernarda Patiño Araujo, Karla Elizabeth Duque Jácome, María Emilia Salgado Báez, Gabriel Villavicencio Logroño, Napoleón Salgado Macías","doi":"10.1111/cob.12705","DOIUrl":null,"url":null,"abstract":"<p><p>People with excess weight and obesity compose 64.5% of the Ecuadorian population. The Allurion Intragastric Balloon (IGB) is a noninvasive weight loss alternative for patients ineligible for other bariatric procedures. The impact of the procedure on weight loss and body composition, along with insertion complications and secondary effects were investigated. This is a single-centre retrospective study of patients who underwent Allurion IGB insertion from July 2020 to March 2021. This study followed 167 patients for 12 months after EIGB insertion. Our sample had a mean initial weight of 83.6 ± 13.8 kg and initial body mass index of 31.3 ± 3.6 kg/m<sup>2</sup>. Percentage total weight loss was 4.65% ± 0.56%, 8.5% ± 4%, 12.29% ± 4.65%, 15.68% ± 5.22%, 17.14% ± 6.05%, and 14.68% ± 18.02% for months 1, 2, 3, 4, 6 and 12, respectively. In the fourth month, 92 patients (56.4%) had lost ≥50% excess body weight; at month 6, 104 patients (67.5%) achieved this goal. Regarding body composition, body fat percentage started at 38.99% ± 7.92%, and at month 6 was 35.67% ± 6.84%, this was the only significance in the statistical analysis.This study aligns with the literature's safety and efficacy results for the Allurion IGB while illustrating the need for further research regarding weight behaviour after its expulsion.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":" ","pages":"e12705"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Obesity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cob.12705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

People with excess weight and obesity compose 64.5% of the Ecuadorian population. The Allurion Intragastric Balloon (IGB) is a noninvasive weight loss alternative for patients ineligible for other bariatric procedures. The impact of the procedure on weight loss and body composition, along with insertion complications and secondary effects were investigated. This is a single-centre retrospective study of patients who underwent Allurion IGB insertion from July 2020 to March 2021. This study followed 167 patients for 12 months after EIGB insertion. Our sample had a mean initial weight of 83.6 ± 13.8 kg and initial body mass index of 31.3 ± 3.6 kg/m2. Percentage total weight loss was 4.65% ± 0.56%, 8.5% ± 4%, 12.29% ± 4.65%, 15.68% ± 5.22%, 17.14% ± 6.05%, and 14.68% ± 18.02% for months 1, 2, 3, 4, 6 and 12, respectively. In the fourth month, 92 patients (56.4%) had lost ≥50% excess body weight; at month 6, 104 patients (67.5%) achieved this goal. Regarding body composition, body fat percentage started at 38.99% ± 7.92%, and at month 6 was 35.67% ± 6.84%, this was the only significance in the statistical analysis.This study aligns with the literature's safety and efficacy results for the Allurion IGB while illustrating the need for further research regarding weight behaviour after its expulsion.

可吞咽的 Allurion 胃内球囊对体重和组成的影响:厄瓜多尔的经验。
体重超标和肥胖症患者占厄瓜多尔人口的 64.5%。Allurion胃内球囊(IGB)是一种非侵入性减肥方法,适用于不符合其他减肥手术条件的患者。研究调查了该手术对体重减轻和身体组成的影响,以及插入并发症和继发性影响。这是一项单中心回顾性研究,研究对象是 2020 年 7 月至 2021 年 3 月期间接受 Allurion IGB 植入术的患者。本研究对 167 名患者进行了为期 12 个月的 EIGB 植入术后随访。样本的平均初始体重为 83.6 ± 13.8 千克,初始体重指数为 31.3 ± 3.6 千克/平方米。第 1、2、3、4、6 和 12 个月的总减重百分比分别为 4.65% ± 0.56%、8.5% ± 4%、12.29% ± 4.65%、15.68% ± 5.22%、17.14% ± 6.05% 和 14.68% ± 18.02%。在第 4 个月,92 名患者(56.4%)的多余体重减轻了≥50%;在第 6 个月,104 名患者(67.5%)达到了这一目标。在身体成分方面,体脂率开始时为 38.99% ± 7.92%,第 6 个月时为 35.67% ± 6.84%,这是统计分析中唯一的显著性。这项研究与文献中有关 Allurion IGB 的安全性和有效性结果一致,同时说明有必要进一步研究其排出后的体重行为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Obesity
Clinical Obesity ENDOCRINOLOGY & METABOLISM-
CiteScore
5.90
自引率
3.00%
发文量
59
期刊介绍: Clinical Obesity is an international peer-reviewed journal publishing high quality translational and clinical research papers and reviews focussing on obesity and its co-morbidities. Key areas of interest are: • Patient assessment, classification, diagnosis and prognosis • Drug treatments, clinical trials and supporting research • Bariatric surgery and follow-up issues • Surgical approaches to remove body fat • Pharmacological, dietary and behavioural approaches for weight loss • Clinical physiology • Clinically relevant epidemiology • Psychological aspects of obesity • Co-morbidities • Nursing and care of patients with obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信